NEOS Neos Therapeutics Inc.

2.1
+0.1  (+5%)
Previous Close 2
Open 2.01
Price To Book -3.89
Market Cap 104320236
Shares 49,676,303
Volume 591,014
Short Ratio
Av. Daily Volume 567,714

NewsSee all news

  1. Neos Therapeutics Announces Realignment of Commercial Organization
  2. Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
  3. Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics — What Drives Growth in Today's Competitive Landscape
  4. Edited Transcript of NEOS earnings conference call or presentation 9-Nov-18 1:30pm GMT
  5. Neos Therapeutics (NEOS) Reports Q3 Loss, Lags Revenue Estimates

SEC filingsSee all SEC filings

  1. S-3 - Registration statement under Securities Act of 1933 181229407
  2. 8-K - Current report 181229370
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181223536
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181211987
  5. 8-K - Current report 181209870

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced September 15, 2017.
NT-0201
Attention deficit hyperactivity disorder (ADHD)
Approved January 27, 2016.
Adzenys XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Approval announced June 19, 2017.
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)

Latest News

  1. Neos Therapeutics Announces Realignment of Commercial Organization
  2. Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
  3. Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics — What Drives Growth in Today's Competitive Landscape
  4. Edited Transcript of NEOS earnings conference call or presentation 9-Nov-18 1:30pm GMT
  5. Neos Therapeutics (NEOS) Reports Q3 Loss, Lags Revenue Estimates
  6. Neos Therapeutics: 3Q Earnings Snapshot
  7. Neos Therapeutics Reports Third Quarter 2018 Financial Results
  8. Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock
  9. Neos Therapeutics Announces Proposed Offering of Common Stock
  10. Neos Therapeutics to Host Third Quarter 2018 Financial Results Conference Call on November 9, 2018
  11. How Is Johnson & Johnson’s Neuroscience Business Positioned?
  12. Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
  13. Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)
  14. New Research Coverage Highlights Amtech, Neos Therapeutics, FTD Companies, John B. Sanfilippo & Son, Molecular Templates, and Aevi Genomic Medicine — Consolidated Revenues, Company Growth, and Expectations for 2018
  15. Neos Therapeutics to Present at the Cantor Global Healthcare Conference
  16. Edited Transcript of NEOS earnings conference call or presentation 8-Aug-18 12:30pm GMT

SEC Filings

  1. S-3 - Registration statement under Securities Act of 1933 181229407
  2. 8-K - Current report 181229370
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181223536
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181211987
  5. 8-K - Current report 181209870
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173212
  7. 8-K - Current report 181171338
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 181170469
  9. SC 13G - Statement of acquisition of beneficial ownership by individuals 181168456
  10. 8-K - Current report 181168447